SCA37_DAB1

Gene
DAB1
Disease
SCA37
Inheritance
AD
Classification
Strong
Total Score
13
Publications Reviewed
2
Publication Span
0.99 years
Last Updated
08/18/2025
Curator(s)
Laurel Hiatt, Elbay Aliyev, Harriet Dashnow

Description

Spinocerebellar ataxia type 37 (SCA37) is an autosomal dominant, generally pure cerebellar ataxia associated with an unstable intronic ATTTC pentanucleotide insertion in the non-coding/regulatory region of DAB1. Reported pathogenic alleles place an ATTTC insertion within a polymorphic ATTTT tract, whereas ATTTT-only alleles are non-pathogenic. Available evidence includes familial segregation and shared haplotypes in Portuguese and Spanish kindreds, absence of the ATTTC mutation from control/healthy relatives, repeat-size effects on age at onset, DAB1 transcript dysregulation/RNA switch in SCA37 cerebellum, AUUUC RNA aggregation in transfected human cells, and AUUUC repeat toxicity in zebrafish embryos.

Genetic evidence

Total: 8.5

Singular EvidenceProbandsPMID:28686858 PMID:299391986PMID:28686858 identified the DAB1 ATTTC insertion in three large Portuguese SCA37 families and three additional pedigrees sharing the disease haplotype, with 35 affected individuals from the initial three kindreds and six affected individuals from the additional pedigrees. PMID:29939198 reported four Spanish SCA37 families with 25 affected individuals and seven at-risk asymptomatic carriers carrying the ATTTC repeat mutation.
Collective EvidenceAllelePMID:299391981In four Spanish SCA37 kindreds, 25 affected and seven at-risk asymptomatic carriers had ATTTC insertions of 46–71 and 49–62 repeats, respectively; in males, larger repeat size correlated with earlier onset (r = 0.96, p < 0.0001), with small repeat increases observed in transmissions.
Collective EvidenceSegregationPMID:28686858 PMID:299391981.5PMID:28686858 mapped SCA37 to chromosome 1p32.2 in three Portuguese families, with maximum multipoint LOD scores of 5.1, 4.4, and 2.2, and showed that the DAB1 ATTTC insertion segregated with disease in all studied families. PMID:29939198 independently showed segregation of the DAB1 ATTTC mutation with disease in four Spanish SCA37 families.
StatisticsCase-control dataPMID:299391980The ATTTC mutation was identified in SCA37 families and was absent from 28 healthy relatives studied; the study also screened a cohort of ataxia patients to identify additional SCA37 pedigrees sharing the DAB1-region haplotype. No additional score was awarded as this study has been scored under other evidence types.
4 rows

Experimental evidence

Total: 4.5

FunctionBiochemical functionPMID:286868580.5Gene-level support: DAB1 is a reelin signal transducer required for accurate neuronal positioning in cerebellar, hippocampal, and cortical development; DAB1 transcripts spanning the repeat region encode the functional PID/PTB receptor-binding domain. This evidence supports the role of the gene.
FunctionProtein interactionPMID:286868580.5Gene-level support: DAB1 functions in the reelin pathway through an N-terminal PID/PTB domain involved in reelin receptor binding; the paper does not directly show TR-specific disruption of protein interactions. This evidence supports the role of the gene.
FunctionRegulatory impactPMID:286868581The ATTTC insertion lies within 5′ UTR introns of DAB1 transcripts expressed in adult cerebellum; transcript analyses showed alternative promoter usage and cerebellar-enriched DAB1 variants spanning the repeat region.
Functional AlterationPatient cellsPMID:286868580Patient fibrobroblasts were used in this study, however the experiment is already scored elsewhere. No score was awarded for this evidence.
Functional AlterationNon-patient cellsPMID:286868580.5HEK293T cells transfected with the pathogenic ins(ATTTC)58 construct formed nuclear AUUUC RNA aggregates by RNA FISH; normal ATTTT-repeat constructs did not, and RNase treatment abolished the signal.
ModelsNon-human model organismPMID:286868582Zebrafish embryos injected with ins(AUUUC)58 RNA showed increased 24 hpf lethality (58.79% versus 14.40–21.51% controls) and markedly reduced normal development (7.76% versus 77.52–85.37% controls).
6 rows

Note: Maximum score caps apply at evidence type, category, and supercategory levels, so section totals may be lower than the raw sum of row scores.